Add BrightSurf on Google Email

Cannabis use and head and neck cancer

A cohort study found an association between cannabis-related disorder and the development of head and neck cancer. The study highlights the need for further research on the mechanism of this association and dose response to support evidence of cannabis use as a risk factor.

SourceJAMA Network·JournalJAMA Otolaryngology–Head & Neck Surgery·DateAug 8, 2024

Bilateral mastectomy and breast cancer mortality

Women with bilateral mastectomy have a greatly diminished risk of contralateral breast cancer, yet experience similar mortality rates as patients treated with lumpectomy or unilateral mastectomy. The study highlights the importance of considering long-term risks and benefits in breast cancer treatment decisions.

SourceJAMA Network·JournalJAMA Oncology·DateJul 25, 2024

Endometriosis typology and ovarian cancer risk

A study of nearly half a million women found that endometriosis was associated with a higher risk of ovarian cancer. The risk was particularly elevated among women with ovarian endometriomas or deep infiltrating endometriosis, with a 19-fold increased risk for certain types of ovarian cancer.

SourceJAMA Network·JournalJAMA·DateJul 17, 2024

Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes

Researchers found GLP-1 receptor agonists lower risks of certain obesity-associated cancers in patients with type 2 diabetes, suggesting potential benefits for cancer prevention in high-risk populations. The study provides preliminary evidence supporting further preclinical and clinical studies to prevent specific obesity-linked cancers.

SourceJAMA Network·JournalJAMA Network Open·DateJul 5, 2024

City of Hope study suggests changing the gut microbiome improves health outcomes for people newly diagnosed with metastatic kidney cancer

Researchers found that a live biotherapeutic product CBM588, when taken orally, can improve health outcomes in people with metastatic kidney cancer. The study, published in Nature Medicine, suggests that the agent may enhance effectiveness of FDA-approved cancer immunotherapies by adjusting the gut microbiome.

SourceCity of Hope·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateJun 28, 2024

Lowering fecal immunochemical test positivity threshold vs multitarget stool RNA testing for colorectal cancer screening

This study found that lowering the fecal immunochemical test positivity threshold can achieve comparable sensitivity and specificity to the multitarget stool RNA test without additional testing. The findings are similar to previous observations with multitarget stool DNA testing, suggesting a potentially simpler screening method.

SourceJAMA Network·JournalJAMA·DateJun 1, 2024

A long-term ketogenic diet accumulates aged cells in normal tissues, a UT Health San Antonio-led study shows

A new study led by UT Health San Antonio found that long-term ketogenic diets can induce senescence, or aged cells, in normal tissues, affecting heart and kidney function. However, an intermittent ketogenic diet regimen eliminated these pro-inflammatory effects.

SourceUniversity of Texas Health Science Center at San Antonio·JournalScience Advances·TypeExperimental study·DateMay 17, 2024

Aspirin vs placebo as adjuvant therapy for breast cancer

A randomized clinical trial of 3,020 patients with high-risk nonmetastatic breast cancer found daily aspirin therapy had no effect on breast cancer recurrence or survival in early follow-up. Aspirin should not be recommended as an adjuvant breast cancer treatment despite its potential benefits and wide availability

SourceJAMA Network·JournalJAMA·DateApr 29, 2024

New urine-based test detects high-grade prostate cancer, helping men avoid unnecessary biopsies

Researchers have developed a new urine-based test that identifies high-grade prostate cancer by analyzing 18 genes linked to the disease. The test, called MyProstateScore2.0, was shown to be nearly 100% correct at ruling out aggressive cancers and helped avoid up to 41% of unnecessary biopsies.

SourceMichigan Medicine - University of Michigan·JournalJAMA Oncology·TypeExperimental study·DateApr 18, 2024

Targeting vulnerability in B-cell development leads to novel drug combination for leukemia

Researchers at St. Jude Children's Research Hospital designed a combination therapy to effectively treat relapsed or resistant B-cell leukemia by targeting the developmental stages of cancer cells. The findings revealed that a protein called BCL-2 is a hidden vulnerability in asparaginase-resistant tumor cells.

SourceSt. Jude Children's Research Hospital·JournalCancer Cell·TypeExperimental study·DateApr 8, 2024